Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 4,628 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Single Dose Placebo Clear all

Conditions: Heart Failure
Interventions: Glial growth factor 2/ Neuregulin 1β3, Placebo; Drug · Other
Lead sponsor: Acorda Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: Atlanta, Georgia • Nashville, Tennessee

Conditions: Acute Stroke, Ischemic Stroke, Stroke
Interventions: Recombinant human tissue kallikrein, Placebo for DM199 Solution for Injection; Drug · Other
Lead sponsor: DiaMedica Therapeutics Inc; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 728 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 36
States / cities: Fairhope, Alabama • Arcadia, California • Glendale, California + 29 more

Conditions: Hypertriglyceridemia
Interventions: REGN1500, placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 99 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Dallas, Texas

Conditions: Systemic Sclerosis-Associated PAH
Interventions: Rituximab, Placebo, CMRI, prednisone, methylprednisolone, diphenhydramine, acetaminophen; Biological · Other · Diagnostic Test + 1 more
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 17
States / cities: Stanford, California • Aurora, Colorado • Iowa City, Iowa + 13 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: ORJ-001, Placebo; Drug · Other
Lead sponsor: Oorja Bio, Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Doral, Florida • DuBois, Pennsylvania

Conditions: Analgesic Response
Interventions: morphine sulfate, hydrocodone, hydromorphone HCI, oxycodone, buprenorphine, oral tablet placebo, sublingual tablet placebo; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 20 Years to 50 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Postbariatric Hypoglycemia
Interventions: exendin 9-39, Placebo; Drug · Other
Lead sponsor: Eiger BioPharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 5
States / cities: Palo Alto, California • Aurora, Colorado • Baltimore, Maryland + 2 more

Conditions: Peripheral Artery Disease
Interventions: Beetroot juice, Placebo; Other
Lead sponsor: Northwestern University; Other
Eligibility: 50 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 4
States / cities: Chicago, Illinois • Minneapolis, Minnesota • Charlottesville, Virginia

Conditions: Healthy Volunteers
Interventions: ASP1128, Placebo; Drug
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy Participants
Interventions: PF-06414300, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Generalized Myasthenia Gravis
Interventions: Ravulizumab, Placebo; Biological · Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: Not listed
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 49
States / cities: Phoenix, Arizona • Irvine, California • Loma Linda, California + 43 more

Conditions: Cluster Headache - Episodic and Chronic
Interventions: SOM230, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: Culver City, California • Philadelphia, Pennsylvania

Conditions: Moderate to Severe Glabellar Lines
Interventions: Corabotase, Placebo; Biological
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 17
States / cities: Birmingham, Alabama • Glendale, Arizona • Scottsdale, Arizona + 13 more

Conditions: Seasonal Allergic Rhinitis
Interventions: azelastine hydrochloride and fluticasone propionate, Dymista vehicle; Drug
Lead sponsor: Meda Pharmaceuticals; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 348 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 31
States / cities: Birmingham, Alabama • Little Rock, Alaska • Atlanta, Georgia + 24 more

Conditions: Healthy
Interventions: Ponesimod Placebo, Moxifloxacin Placebo, Ponesimod 10 mg, Ponesimod 20 mg, Ponesimod 40 mg, Ponesimod 60 mg, Ponesimod 80 mg, Ponesimod 100 mg, Moxifloxacin 400 mg; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Hypertension, Pure Autonomic Failure, Multiple System Atrophy
Interventions: Losartan, Captopril, Placebo; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Overweight, Diabetes Mellitus Type 2 in Obese
Interventions: P11187, Placebo; Drug
Lead sponsor: Piramal Enterprises Limited; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Acute Kidney Injury
Interventions: BCT197 Part A, Placebo, BCT197 Part B; Drug
Lead sponsor: Mereo BioPharma; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 6
States / cities: Orange, California • Saginaw, Michigan • Lincoln, Nebraska + 3 more

Conditions: Influenza
Interventions: FluMist, Placebo; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Common Cold, Pharyngitis
Interventions: Acetylsalicylic Acid (Aspirin Complex, BAYE4465) + Pseudoephedrine, Acetylsalicylic Acid (Aspirin, BAYE4465), Pseudoephedrine, Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,016 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 2
States / cities: New York, New York

Conditions: Cytomegalovirus Infections
Interventions: AVX601, Placebo; Biological
Lead sponsor: AlphaVax, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Healthy Volunteers
Interventions: Treprostinil Palmitil Inhalation Powder, Placebo; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Neonatal Encephalopathy, Hypoxic-Ischemic Encephalopathy Mild
Interventions: Darbepoetin Alfa, Normal Saline; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: 1 Hour to 24 Hours
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Metapneumovirus
Interventions: 10^6 PFU rHMPV-Pa vaccine, 10^5 PFU rHMPV-Pa vaccine, Placebo Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Months to 49 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 2
States / cities: Baltimore, Maryland • Seattle, Washington

Search by objective public record fields.

Single Ascending Doses of GGF2 in Patients With Left Ventricular Dysfunction and Symptomatic Heart Failure

Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)

Study to Assess the Safety and Tolerability of Single Doses of REGN1500

Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)

Study of ORJ-001 for the Treatment of IPF

Analgesic Response to Opioid Analgesics in Buprenorphine-Maintained Individuals

Safety and Efficacy of Exendin 9-39 in Patients With Postbariatric Hypoglycemia

BEETroot Juice to Reverse Functional Impairment in PAD

A Study of MA-0217 (ASP1128) in Healthy Adult Subjects and Healthy Elderly Subjects

A Study to Learn How Different Amounts and Forms of the Study Medicine Called PF-06414300 Act in Healthy Adults

Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis

Safety and Efficacy Study of SOM230 s.c. in Cluster Headache

A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows

Safety and Efficacy Trial of Dymista Nasal Spray in Children Ages 4 to 11 With Seasonal Allergic Rhinitis (SAR)

Study of the Electrocardiographic Effects of Ponesimod in Healthy Male and Female Subjects

Contribution of Angiotensin II to Supine Hypertension in Autonomic Failure

Determination of Safety,Tolerability,Pharmacokinetics,Food Effect& Pharmacodynamics of Single & Multiple Doses of P11187

Safety & Efficacy of BCT197 in Patients Undergoing Cardiac Surgery

Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults

Placebo and Active Controlled Study to Assess Efficacy and Tolerability of Aspirin Plus Pseudoephedrine

A Clinical Trial of an Alphavirus Replicon Vaccine for Cytomegalovirus (CMV)

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder (TPIP) in Healthy Participants

Mild Encephalopathy in the Newborn Treated With Darbepoetin

Evaluation of the Safety and Immunogenicity of a Live Attenuated Human Metapneumovirus Vaccine